In the Acute Coronary Syndrome Drug Market, the Uptake of Eli Lilly/Daiichi Sankyo's Effient Will Be Constrained by the Widespread Use of Astrazeneca's Brilinta
Advertisement
Effient's Drawbacks Include a High Rate of Bleeding and Lack of Reversibility, According to New Findings from Decision Resources
